The First Affiliated Hospital with Nanjing Medical University
Age
18–69
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Histologically or cytologically confirmed breast cancer.
2. Patients considered by the investigator to be suitable for neoadjuvant or adjuvant chemotherapy with an anthracycline- and/or taxane-containing regimen administered in 21-day cycles, and expected to receive at least 3 chemotherapy cycles.
3. Age ≥18 years and \<70 years.
4. Body weight ≥45 kg.
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
6. Adequate baseline white blood cell and neutrophil counts before chemotherapy: white blood cell count (WBC) ≥3.5 × 10\^9/L and absolute neutrophil count (ANC) ≥1.5 × 10\^9/L.
7. Expected survival ≥3 months.
8. Willing to participate in the study, able to understand the study procedures, and able to provide written informed consent.
You may not be if
1. Previous or anticipated large-field radiotherapy involving \>25% of the total bone marrow.
2. Significant dysfunction of major organs, including heart, lung, liver, or kidney; liver function abnormalities defined as ALT or total bilirubin \>2.5 × ULN, or \>5 × ULN in patients with liver metastases; hepatitis B virus infection, hepatitis C virus infection, or cirrhosis; or serum creatinine \>1.5 × ULN.
3. Pregnant or breastfeeding women.
4. Previous or ongoing bone marrow transplantation or organ transplantation.
5. Known hypersensitivity to G-CSF or any component of a G-CSF product.
6. Patients who are unable to reliably understand or report their medical condition.
7. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.
Clareo Health | Correlation Between ANC and Bone Pain in Breast Cancer Patients Receiving Long-Acting G-CSF
